阿布西替尼的功效与作用与副作用？

Clinical studies have shown that 100 and 200 mg/d treatment can significantly improve the itching symptoms in patients with moderate to severe atopic dermatitis on the first day. After 12 weeks of treatment, the improvement rates of itching in the abusitinib 100 and 200 mg/d treatment groups were 37.4% to 45.2% and 45.2% to 57.1%, respectively, and the proportions of patients reaching EASI-75 were 39.7% to 44.5% and 61.0% to 62.7%, respectively, which were significantly higher than those in the placebo group.

The common side effects of this drug include nasopharyngitis, nausea, headache, herpes simplex, elevated blood creatinine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, oropharyngeal pain, influenza, and gastroenteritis.

About abrocitinib

Abrocitinib is an oral, selective JAK1 inhibitor used to treat atopic dermatitis (AD). Oral abisitinib demonstrated good efficacy and tolerability in patients with moderate to severe atopic dermatitis. The U.S. Food and Drug Administration (FDA) approved the marketing of Absitinib on January 14, 2022, and the China National Medical Products Administration (NMPA) approved the marketing of Absitinib on April 11, 2022.

The role of Absitinib

Absitinib is the first oral and effective selective JAK1 small molecule inhibitor for the treatment of psoriasis. It can regulate the expression of a variety of cytokines involved in the pathophysiological process of psoriasis, including interleukins IL-4, IL-13, IL-31, IL-22 and thymic stromal lymphopoietin (TSLP), thus exerting a therapeutic effect. Psoriasis is a chronic autoimmune disease in which patients often present with symptoms such as abnormal skin proliferation, erythema, and scale. The mechanism of action of Absitinib is expected to effectively improve these symptoms and improve patients' quality of life. If you have needs or questions about psoriasis treatment, it is recommended to consult a doctor for professional advice.

Efficacy of Absitinib

Jade Mono-1 is a 12-week, multi-center, double-blind, placebo-controlled, randomized Phase III clinical trial (NCT03349060) [1], which evaluates the efficacy and safety of abisitinib in the treatment of adolescent and adult patients with moderate to severe AD for 12 weeks based on the Phase IIb clinical trial. The primary endpoints of the trial are the proportion of patients who obtained an investigator's global assessment of 0/1 at week 12 and the proportion of patients who achieved EASI-75 compared with baseline.

387 patients were included in the study and were assigned to oral abisitinib 200 mg, 100 mg and placebo according to 2:2:1. The results showed that by week 12, the proportion of oral abisitinib 200 mg and 100 mg groups receiving investigator global assessment of 0/1 was significantly higher than that of the placebo group, 44% (P<0.0001) and 24% (P =0.0037). By week 12, the EASI-75 response proportions in the oral abositinib 200 mg and 100 mg groups were significantly higher than those in the placebo group, 63% (P <0.0001) and 40% (P<0.0001) respectively. The incidence of serious adverse reactions in the oral abositinib 200 mg and 100 mg groups was very low (<4%). , but a mild decrease in platelets was observed, and the mechanism remains unclear.

This study demonstrates that once-daily oral abositinib is effective and well tolerated in adolescents and adults with moderate to severe AD, with a favorable benefit-risk profile.

Side effects of Absitinib

Common side effects of Absitinib found in clinical trials include nasopharyngitis, nausea, headache, herpes simplex, elevated blood creatinine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, oropharyngeal pain, influenza, and gastroenteritis. The following are some suggestions for treatment measures:

1. Nasopharyngitis: You can use salt water gargle or nasal spray to relieve discomfort and avoid excessive nose blowing.

2. Nausea and vomiting: Try to avoid taking medicine on an empty stomach. You can choose to take medicine after meals, eat in multiple meals, and avoid eating spicy and greasy foods.

3. Headache and dizziness: Rest, get enough sleep, and avoid staying in the same posture for a long time. If dizziness is severe, seek medical advice nearby.

4. Herpes simplex: You may need to use antiviral drugs for treatment. If you continue to be uncomfortable, seek medical treatment in time.

5. Elevation of serum creatinine phosphokinase: Renal function needs to be closely monitored. If it continues to increase, the drug dose may need to be adjusted or discontinued.

6. Urinary tract infection: Drink plenty of water and pay attention to personal hygiene. If symptoms such as frequent urination and urgency occur, seek medical treatment in time.

7. Fatigue: Arrange work and rest time reasonably, exercise appropriately, and maintain a good attitude.

8. Acne: Keep your face clean and avoid squeezing. You can try to use skin care products containing anti-acne ingredients.

9. Oropharyngeal pain: rinse mouth with warm water and avoid eating hot or cold foods.

10. Influenza and gastroenteritis: Pay attention to personal hygiene, drink plenty of water, and avoid contact with pathogens. If symptoms are severe, seek medical treatment in time.

The above treatment measures are for reference only, and the specific treatment methods should be based on the patient's specific situation and the doctor's recommendations. If severe discomfort or persistent side effects occur, you should seek medical help promptly.

References

[1] Zhu Xu, Wu Wenzhong. Research progress of abisitinib in the treatment of moderate and severe atopic dermatitis [J]. Journal of Dermatology and Venereology Diagnosis and Treatment, 2023, 30(04): 372-376.

Hot article recommendations: